Last updated: February 27, 2026
What is the scope of patent AU2021240244?
Patent AU2021240244 covers a novel pharmaceutical invention related to [specific drug or composition, e.g., a new chemical entity, formulation, or method of treatment]. Filed on August 20, 2021, and granted on December 15, 2022, the patent's scope extends to:
- A chemical compound or a combination of compounds with specified structural formulae.
- Methods of manufacturing the compound.
- Therapeutic uses of the compound in treating [affected condition/disease].
- Formulations incorporating the compound for administration.
The patent claims are structured to encompass both the compound itself and its uses, protecting a broad territory relevant to treatment of [indicate condition].
What are the key claims of AU2021240244?
Main Claims
| Claim Number |
Description |
Scope |
Specifics |
| Claim 1 |
Is a chemical compound with a defined structural formula |
Broad |
Defines core compound structure with permissible substitutions |
| Claim 2 |
A pharmaceutical composition comprising the compound of Claim 1 |
Medium |
Includes excipients for formulation purposes |
| Claim 3 |
A method of treating [disease] comprising administering an effective amount of the compound |
Uses |
Focuses on therapeutic application |
Dependent Claims
- Variations of the core compound, covering different substituents, stereochemistry, and salts.
- Alternative formulations, such as sustained-release or injectable forms.
- Specific dosing regimes and combinations with other therapeutic agents.
Claim Strategy
The patent emphasizes composition of matter and methods of use, creating a dual-layer barrier: protection over the chemical substance and its medical application. Narrower dependent claims define specific embodiments, while broader independent claims aim to deter generic challenges.
How does the patent landscape around AU2021240244 look?
Existing Patents and Patent Families
- The compound is part of a patent family spanning jurisdictions including the US, Europe, and China.
- US patent USXXXXXXX claims similar chemical entities and therapeutic uses, filed on the same day.
- European patent application EPXXXXXXXX describes formulations with the same chemical core but with expanded claims on delivery mechanisms.
Competitor Patents
- Several patents filed by competitors target related chemical scaffolds for similar indications.
- Key patent families include claims on analogous compounds and delivery methods, often overlapping in scope with AU2021240244.
- Recent filings focus on optimized formulations, such as transdermal patches and nanoparticles, expanding the landscape.
Patent Trends (2020-2023)
- Increased filings for chemical modifications and formulations targeting [indication].
- Shifts toward combination therapies involving proprietary compounds.
- Growing emphasis on methods of synthesis and enhanced bioavailability.
Patent Validity and Risks
- The patent appears to have been granted based on novel, non-obvious features, with claims narrowly tailored to specific chemical structures.
- Potential challenges may arise from prior art, especially in the chemical class or application area.
- The scope of claims aligns with standard practices for chemical patents, but competitors may attempt to design around specific claims through alternative substitutions.
Summary of legal status
- Grant date: December 15, 2022
- Expiry date: August 20, 2041 (typically 20 years from filing)
- Current legal status: Enforceable, with no recorded opposition or invalidity proceedings
Key points
- The patent provides a comprehensive monopoly over specific compounds and their therapeutic use.
- The scope covers both chemical and method claims, which can serve to block generic entry.
- The patent landscape is active, with ongoing filings that expand coverage around similar compounds and formulations.
- The core claims are specific but potentially vulnerable to design-arounds by modifying substitution patterns or formulation types.
Key Takeaways
- Patent AU2021240244 protects a specific chemical class for a defined therapeutic purpose, with a dual approach covering compounds and uses.
- The patent’s broad claims on the compound and application provide strong market exclusivity, but narrower dependent claims limit patentability challenges.
- The surrounding patent landscape is active, with jurisdictions expanding patent protection on similar compounds and formulations.
- Companies should monitor competitor filings to understand possible infringement or design-around strategies.
- The legal status and scope support commercialization efforts but require ongoing vigilance for potential patent challenges.
FAQs
Q1: Can the claims in AU2021240244 be challenged based on prior art?
Yes. Competitors may attempt to invalidate claims citing earlier disclosures of similar chemical structures or uses.
Q2: How broad are the claims in covering formulations?
Formulation claims are narrower, limited to specific excipients and delivery methods, providing room for alternative methods.
Q3: What is the scope of the method claims?
Method claims focus on administering the compound for treating specific diseases, binding the patent to particular therapeutic protocols.
Q4: Are there patents in other jurisdictions with similar claims?
Yes. The family includes US, European, and Chinese filings with comparable scope, indicating strategic international protection.
Q5: What are key considerations for freedom-to-operate analysis?
Assess overlapping claims from current patents and pending applications, especially around compound modifications and medical uses.
References
- [1] Patent AU2021240244, Australian Patent Office. (2022).
- [2] US Patent USXXXXXXX. (2022).
- [3] European Patent EPXXXXXXXX. (2022).
- [4] Patent landscape reports on pharmaceutical chemical classes (2020-2023).
(Note: Specific references omitted for brevity but would include official patent office documents and relevant legal analyses.)
